Thursday, 16 Aug 2018

You are here

Low-dose Bactrim Safe with Methotrexate in AAV

A high proportion of GPA patients receive pneumocystis prophylaxis, usually with TMP-SMX (Bactrim), and drug interactions are always a concern.  

Given that many GPA patients are treated with methotrexate, we often wonder – can my patient safely receive TMP-SMX prophylaxis in conjunction with methotrexate? This concern exists because both methotrexate and TMP work by inhibiting dihydrofolate reductatse and thus it is not surprising that potential for bone marrow toxicity exists. Dr. Tamaki (Japan) presented an abstract this morning looking at safety of low dose TMP-SMX (160mg-800 mg 3x/week or 80mg-400mg/day) when given with methotrexate in patients with AAV.

They performed a retrospective chart review at the Cleveland Clinic (2002-2017) and compared variables between patients receiving methotrexate both with and without TMP-SMX and found the rates of methotrexate discontinuation to be similar between both groups with no differences in reasons for discontinuation (side effect, infection, switching to another medication to treat AAV, methotrexate withdrawal after sustained remission, patient discontinued). Side effects occurred in 8.6% of the methotrexate only group and 7.1% of the methotrexate + TMP-SMX group.

This Cleveland Clinic experience reassures us that it seems safe to administer methotrexate with low dose TMP-SMX, although close monitoring of these patients is key.  

 

Add new comment

More Like This

Hydroxychloroquine Being Over-Dosed with New Guidelines?

Hydroxychloroquine retinopathy prevention guidelines have revised from ideal body weight-based dosing to actual body weight-based dosing; the question remains whether these have been adopted in clinical practice. A database of nearly 21,000 new HCQ users from a UK general population database studied HCQ dosing and use between 2007 and 2016. Specifically they examined whether users were subjected to excess HCQ dosing per ophthalmology guidelines (defined by exceeding 6.5 mg/kg of IBW and 5.0 mg/kg of ABW).

NSAID Use Around Conception Increases Miscarriage Risk

A study from the American Journal of Obstetrics & Gynecology analyzed pregnant women from the Kaiser Permanente healthcare system and compared newly pregnant women who took non-steroidal anti-inflammatory drugs or acetaminophen or neither showed that using NSAIDs around conception carried a more than four-fold higher risk of early miscarriage. (Citation source: http://bit.ly/2tqNWN6)

Could Measuring Drug Levels with TNF Treatment Hurt Your Patients?

Our colleagues in gastroenterology measure drug levels with certain biologics used in inflammatory bowel disease in order to increase the dose for optimal benefit if the patient has a low trough level (i.e. targeting drug level).

There have been GI trials with T2T with drug levels but they are not always suggesting that the strategy is superior to usual care. Also, this is really not a common practice in rheumatology.

Methotrexate Update

I was delighted to see that investigators presenting work at EULAR 2018 haven’t lost interest in our old friend methotrexate, with a number of abstracts examining issues of safety, dose and route of administration.

Low incidence of methotrexate induced liver abnormalities

Cancer Therapies Inducing Immune-Related Adverse Events (irAEs)

Recent shifts in the cancer treatment paradigm towards immune therapies has led to wide implementation of the novel immune check point inhibitors (ICI) in the treatment of multiple types of advanced cancer.

While being quite effective in oncology, these checkpoint inhibitors have led to the emergence of a quite unique spectrum of rheumatologic conditions presented under the umbrella of immune-related adverse events (irAEs).